In Vivo Inhibition of TRPC6 by SH045 Attenuates Renal Fibrosis in a New Zealand Obese (NZO) Mouse Model of Metabolic Syndrome
Open Access
- 20 June 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (12) , 6870
Abstract
Metabolic syndrome is a significant worldwide public health challenge and is inextricably linked to adverse renal and cardiovascular outcomes. The inhibition of the transient receptor potential cation channel subfamily C member 6 (TRPC6) has been found to ameliorate renal outcomes in the unilateral ureteral obstruction (UUO) of accelerated renal fibrosis. Therefore, the pharmacological inhibition of TPRC6 could be a promising therapeutic intervention in the progressive tubulo-interstitial fibrosis in hypertension and metabolic syndrome. In the present study, we hypothesized that the novel selective TRPC6 inhibitor SH045 (larixyl N-methylcarbamate) ameliorates UUO-accelerated renal fibrosis in a New Zealand obese (NZO) mouse model, which is a polygenic model of metabolic syndrome. The in vivo inhibition of TRPC6 by SH045 markedly decreased the mRNA expression of pro-fibrotic markers (Col1α1, Col3α1, Col4α1, Acta2, Ccn2, Fn1) and chemokines (Cxcl1, Ccl5, Ccr2) in UUO kidneys of NZO mice compared to kidneys of vehicle-treated animals. Renal expressions of intercellular adhesion molecule 1 (ICAM-1) and α-smooth muscle actin (α-SMA) were diminished in SH045- versus vehicle-treated UUO mice. Furthermore, renal inflammatory cell infiltration (F4/80+ and CD4+) and tubulointerstitial fibrosis (Sirius red and fibronectin staining) were ameliorated in SH045-treated NZO mice. We conclude that the pharmacological inhibition of TRPC6 might be a promising antifibrotic therapeutic method to treat progressive tubulo-interstitial fibrosis in hypertension and metabolic syndrome.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (DFG) (GO766/18-2, GO 766/12-3, SFB 1365, NU 53/12-2, TRR 152)
This publication has 39 references indexed in Scilit:
- Chronic kidney disease: global dimension and perspectivesThe Lancet, 2013
- A TRPC6-Dependent Pathway for Myofibroblast Transdifferentiation and Wound Healing In VivoDevelopmental Cell, 2012
- Diet Dependence of Diabetes in the New Zealand Obese (NZO) Mouse: Total Fat, But not Fat Quality or Sucrose Accelerates and Aggravates DiabetesExperimental and Clinical Endocrinology & Diabetes, 2010
- Association of Trypanolytic ApoL1 Variants with Kidney Disease in African AmericansScience, 2010
- Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal ResearchPLOS Biology, 2010
- Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathyKidney International, 2009
- The calcium‐conducting ion channel transient receptor potential canonical 6 is involved in macrophage inflammatory protein‐2‐induced migration of mouse neutrophils*Acta Physiologica, 2008
- Fibroblasts in Kidney Fibrosis Emerge via Endothelial-to-Mesenchymal TransitionJournal of the American Society of Nephrology, 2008
- TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal functionNature Genetics, 2005
- Myofibroblasts and mechano-regulation of connective tissue remodellingNature Reviews Molecular Cell Biology, 2002